FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.

Cancers (Basel) · 2020 · PMC7072445 · PMID 32069837

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This is highlighted by the statistically highly significant differences in the application of special regulatory designations and pathways that we found.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.